Trulicity (dulaglutide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of Use:
- Not recommended as first-line therapy for patients inadequately controlled on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans. Prescribe only if potential benefits outweigh potential risks. Has not been studied in patients with a history of pancreatitis; consider another antidiabetic therapy. Not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Not a substitute for insulin. Has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis. Not for patients with pre-existing severe gastrointestinal disease. Has not been studied in combination with basal insulin.

Please see Important Safety Information for Trulicity, including Boxed Warning about possible thyroid tumors including thyroid cancer, on following page and accompanying Prescribing Information and Medication Guide. Please see Instructions for Use included with the pen.
Important Safety Information for Trulicity®

**WARNING: RISK OF THYROID C-CELL TUMORS**

In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether Trulicity causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.

Trulicity is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of Trulicity and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Trulicity.

Trulicity is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to dulaglutide or any of the product components.

**Risk of Thyroid C-cell Tumors:** Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist (GLP-1 RA), have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 RA use in humans. If serum calcitonin is measured and found to be elevated or dyspepsia (2.3%, 4.1%, 5.8%), and fatigue (2.6%, 4.2%, 5.6%).

**Gastric emptying** is slowed by Trulicity, which may impact absorption of concomitantly administered oral medications. Use caution when oral medications are used with Trulicity. Drug levels of oral medications with a narrow therapeutic index should be adequately monitored when concomitantly administered with Trulicity. In clinical pharmacology studies, Trulicity did not affect the absorption of the tested, orally administered medications to a clinically relevant degree.

**Pregnancy:** There are no adequate and well-controlled studies of Trulicity in pregnant women. Use only if potential benefit outweighs potential risk to fetus.

**Nursing Mothers:** It is not known whether Trulicity is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue Trulicity, taking into account the importance of the drug to the mother.

**Pediatric Use:** Safety and effectiveness of Trulicity have not been established and use is not recommended in patients less than 18 years of age.

**Please see accompanying Prescribing Information, including Boxed Warning about possible thyroid tumors including thyroid cancer, and Medication Guide.**

**Please see Instructions for Use included with the pen.**

DG HCP ISI 20APR2015

---

**References**


Lantus® is a registered trademark of Sanofi-Aventis U.S. LLC. Victoza® is a registered trademark of Novo Nordisk A/S.

As a result of enacted state and federal legislation, if you are a prescriber or other licensed healthcare professional with an active license from MA, MN, and/or VT, a Veterans Affairs employee, and/or a state government employee, you may be restricted from accepting industry-provided food/beverage and/or educational item(s). Please consult your state or federal regulations or ethics laws.

This program is intended only for invited healthcare professionals (HCPs) or other appropriate personnel for whom the information that is being presented will be relative to their practice. We regret that spouses or other guests cannot be accommodated. MedLearning, our contracted third parties, or activity sponsors will not sell or rent your personally identifiable information. This program is sponsored by and the speaker is presenting on behalf of Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.

PP-DG-US-0512 04/2016 PRINTED IN USA ©Lilly USA, LLC 2016. All rights reserved.

Trulicity® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. Trulicity is available by prescription only.